Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer

• Verfasst von: Kuru, Timur Hasan [VerfasserIn]
• Verfasst von: Huber, Johannes [VerfasserIn]
• Verfasst von: Hatiboglu, Gencay [VerfasserIn]
• Verfasst von: Wagener, Nina [VerfasserIn]
• Verfasst von: Pahernik, Sascha [VerfasserIn]
• Verfasst von: Hadaschik, Boris [VerfasserIn]
• Verfasst von: Hohenfellner, Markus [VerfasserIn]
• Titel: Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer
• Titelzusatz: good clinical response
• Verf.angabe: Timur Hasan Kuru, Johannes Huber, Gencay Hatiboglu, Nina Wagener, Sascha Pahernik, Boris Hadaschik, Markus Hohenfellner
• E-Jahr: 2011
• Jahr: January 25, 2011
• Umfang: 5 S.
• Fussnoten: Gesehen am 11.07.2022
• Titel Quelle: Enthalten in: Urologia internationalis
• Ort Quelle: Basel : Karger, 1955
• Jahr Quelle: 2011
• Band/Heft Quelle: 86(2011), 3, Seite 256-260
• ISSN Quelle: 1423-0399
• DOI: doi:10.1159/000322545
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1809714362

Abstract

Purpose: To report our experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for patients with metastatic renal cell carcinoma (mRCC). Patients and Methods: In our prospectively maintained tumor registry, we identified 6 mRCC patients with temsirolimus in >1st-line systemic therapy. Patients were followed by weekly clinical and laboratory examination during admission of temsirolimus. Re-staging with chest CT and abdominal MRI was performed every 3 months. Results: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, pneumonitis was observed in 4 of 6 patients. Drug-related pneumonitis led to severe dyspnea, with the result that treatment with temsirolimus had to be interrupted for a short period of time in 2 patients and discontinued in 1 patient. Conclusions: Temsirolimus proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of pneumonitis must not be underestimated.